The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability

Renal Failure

Volumn 30, Issue 2, 2008, Pages 161-167

  Theodoridis, M ^a,b   Passadakis, P ^a   Kriki, P ^a   Gioka, T ^a   Panagoutsos, S ^a   Mourvati, E ^a   Thodis, E ^a   Kantartzi, K ^a   Vargemezis, V ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Bicarbonate; Biocompatible solution; Cancer antigen 125; Mesothelial cell mass; Peritoneal dialysis

Indexed keywords

BICARBONATE; BUFFER; CA 125 ANTIGEN; DIALYSIS FLUID; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; LACTIC ACID;

AGED; ARTICLE; BIOCOMPATIBILITY; CELL VIABILITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DIALYSATE; FEMALE; HUMAN; INNER CELL MASS; MALE; MESOTHELIUM CELL; OSMOSIS; PERITONEUM CELL; PH; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

AGED; BICARBONATES; BIOCOMPATIBLE MATERIALS; BIOLOGICAL MARKERS; CA-125 ANTIGEN; CELL SURVIVAL; COHORT STUDIES; DIALYSIS SOLUTIONS; EPITHELIAL CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONITIS; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 39749139352     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220701808384     Document Type: Article

References (31)

1. Williams JD, Craig KJ, Topley N, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13:470-479.
2. Topley N, Alobaidi HM, Davies M, Coles GA, Williams JD, Lloyd D. The effect of dialysate on peritoneal phagocyte oxidative metabolism. Kidney Int. 1988;34:404-411.
3. Zareie M, Hekking L, Welten AG, et al. Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo. Nephrol Dial Transplant. 2003;18:2629-2637.
4. Breborowicz A, Martis L, Oreopoulos DG. Changes of biocompatibility of dialysis fluid during its dwell in the peritoneal cavity. Perit Dial Int. 1995;15:152-157.
5. Park MS, Kim JK, Holmes C, Weiss MF. Effects of bicarbonate/lactate solution on peritoneal advanced glycosylation end-products accumulation. Perit Dial Int. 2000;20 [Suppl. 5]:33-38.
6. Rippe B, Simonsen O, Heimburger O, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int. 2001;59:348-357.
7. Lage C, Pischetsrieder M, Aufricht C, Jörres A, Schilling H, Passlick-Deetjen J. First in vitro and in vivo experiences with stay safe balance, a pH-neutral solution in a dual-chambered bag. Perit Dial Int. 2000;20[Suppl. 5]:28-32.
8. Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT. Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis. Adv Perit Dial. 1997;13:17-22.
9. Pannekeet MM, Hiralall JK, Struijk DG, Krediet RK. Longitudinal follow-up of CA 125 in peritoneal effluent. Kidney Int. 1997;51:888-893.
10. Heimbürger O, Rippe B, Christensson A, Haraldsson B, Simonsen O, Stelin G, et al. Dialysate CA125, hyaluronan (HA) and procollagen 1 peptide (PICP) in CAPD patients during 12 months treatment with a PD fluid containing less toxic glucose degradation products [Abstract]. Perit Dial Int. 1999;19(Suppl. 1):S80.
11. Krediet RT. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int. 2001;21(6)560-567
12. Combet S, Miyata T, Moulin P, et al. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol. 2000;11:717-728.
13. Mateijsen MA, van der Wal AC, Hendriks PM, et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int. 1999;19:517-525.
14. Honda K, Nitta K, Horita S, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration. Nephrol Dial Transplant. 1999;14:1541-1549.
15. Honda K, Nitta K, Horita H, et al. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron. 1996;72:171-176.
16. Gotloib L, Wajsbrot V, Shostak A, et al. Population analysis of mesothelium in situ and in vivo exposed to bicarbonate-buffered peritoneal dialysis fluid. Nephron. 1996; 73:219-227.
17. Gotloib L, Waisbrut V, Shostak A, et al. Biocompatibility of dialysis solutions evaluated by histochemical techniques applied to mesothelial cell imprints. Perit Dial Int. 1993;13:201-207.
18. De Fijter CWH, Verbrugh HA, Peters EDJ, et al. In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD. Clin Nephrol. 1993;39:75-80.
19. Mackenzie RK, Jones S, Moseley A, et al. In vivo exposure to bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function. Am J Kidney Dis. 2000;35:112-121.
20. MacKenzie RK, Holmes CJ, Moseley A, et al. Bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFalpha secretion. J Am Soc Nephrol. 1998;9:1499-1506.
21. Ho-Dac-Pannekeet MM, Krediet RT. Inflammatory changes in vivo during CAPD: What can the effluent tell us? Kidney Int. 1996;50 (Suppl. 56):S12-S16.
22. Krediet RT, Pannekeet MM, Zemel D, et al. Markers of peritoneal membrane status. Perit Dial Int. 1996;16:S42-S49.
23. Yamagata K, Tomida C, Koyama A. Intraperitoneal hyaluronan production in stable continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1999;19:131-137.
24. Zweers MM, de Waart DR, Smit W, et al. Growth factors VEGF and TGF-beta1 in peritoneal dialysis. J Lab Clin Med. 1999;134:124-132.
25. Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, et al. Longitudinal follow-up of CA125 in peritoneal effluent. Kidney Int. 1997;51:888-893.
26. Topley N. Membrane longevity in peritoneal dialysis: Impact of infection and bio-incompatible solutions. Adv Ren Replace Ther. 1998;5:179-184.
27. Topley N, Williams JD. The role of the peritoneal membrane in the control of inflammation in the peritoneal cavity. Kidney Int. 1994;46 (Suppl. 48):S71-S78.
28. Witowski J, Korybalska K, Wisniewska J, et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol. 2000;11:729-739.
29. Nomoto Y, Kawaguchi Y, Kubo H, et al. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: A report on the Japanese sclerosing encapsulating peritonitis study group. Am J Kidney Dis. 1996;28:420-427.
30. Cappelli G, Bandiani G, Cancarini GC, et al. Low concentrations of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: Prospective cross-over study with a three-compartment bag. Adv Perit Dial. 1999;15:238-242.
31. Wieslander AP. Cytotoxicity of peritoneal dialysis fluid - is it related to glucose breakdown products? Nephrol Dial Transplant. 1996;11:958-959.